PL4304631T3 - Leczenie chorób oczu kwasową oksydazą fruktozyloaminową - Google Patents
Leczenie chorób oczu kwasową oksydazą fruktozyloaminowąInfo
- Publication number
- PL4304631T3 PL4304631T3 PL22711023.6T PL22711023T PL4304631T3 PL 4304631 T3 PL4304631 T3 PL 4304631T3 PL 22711023 T PL22711023 T PL 22711023T PL 4304631 T3 PL4304631 T3 PL 4304631T3
- Authority
- PL
- Poland
- Prior art keywords
- fructosyl
- treatment
- amino acid
- eye diseases
- acid oxidase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21161313 | 2021-03-08 | ||
| PCT/EP2022/055727 WO2022189344A1 (en) | 2021-03-08 | 2022-03-07 | Treatment of eye diseases with fructosyl-amino acid oxidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4304631T3 true PL4304631T3 (pl) | 2025-04-28 |
Family
ID=74859821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22711023.6T PL4304631T3 (pl) | 2021-03-08 | 2022-03-07 | Leczenie chorób oczu kwasową oksydazą fruktozyloaminową |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240216480A1 (pl) |
| EP (1) | EP4304631B1 (pl) |
| JP (1) | JP7758376B2 (pl) |
| CN (1) | CN116981472A (pl) |
| AU (1) | AU2022233704B2 (pl) |
| CA (1) | CA3210369A1 (pl) |
| ES (1) | ES2994793T3 (pl) |
| PL (1) | PL4304631T3 (pl) |
| WO (2) | WO2022189357A1 (pl) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7153666B2 (en) | 2003-07-17 | 2006-12-26 | General Atomics | Methods and compositions for determination of glycated proteins |
| EP2155157A1 (en) | 2007-06-11 | 2010-02-24 | Chanel Parfums Beauté | Cosmetic use of active agents for stimulating the expression of fn3k and/or fn3k rp to improve the skin's barrier function |
| CN206975046U (zh) | 2017-05-26 | 2018-02-06 | 海格德生物科技（深圳）有限公司 | 糖化血红蛋白检测试纸条 |
| WO2019149648A1 (en) | 2018-01-30 | 2019-08-08 | Universiteit Gent | Compositions for use to treat cataract |
| AU2019337382B2 (en) | 2018-09-14 | 2024-10-17 | Universiteit Gent | Compositions for use to treat advanced glycation end products-dependent ocular diseases |
-
2022
- 2022-03-07 PL PL22711023.6T patent/PL4304631T3/pl unknown
- 2022-03-07 AU AU2022233704A patent/AU2022233704B2/en active Active
- 2022-03-07 ES ES22711023T patent/ES2994793T3/es active Active
- 2022-03-07 CA CA3210369A patent/CA3210369A1/en active Pending
- 2022-03-07 US US18/549,476 patent/US20240216480A1/en active Pending
- 2022-03-07 EP EP22711023.6A patent/EP4304631B1/en active Active
- 2022-03-07 WO PCT/EP2022/055753 patent/WO2022189357A1/en not_active Ceased
- 2022-03-07 WO PCT/EP2022/055727 patent/WO2022189344A1/en not_active Ceased
- 2022-03-07 CN CN202280019614.7A patent/CN116981472A/zh active Pending
- 2022-03-07 JP JP2023554855A patent/JP7758376B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022189357A1 (en) | 2022-09-15 |
| WO2022189344A1 (en) | 2022-09-15 |
| EP4304631B1 (en) | 2024-10-30 |
| ES2994793T3 (en) | 2025-01-31 |
| EP4304631C0 (en) | 2024-10-30 |
| US20240216480A1 (en) | 2024-07-04 |
| CN116981472A (zh) | 2023-10-31 |
| AU2022233704B2 (en) | 2024-09-26 |
| EP4304631A1 (en) | 2024-01-17 |
| JP7758376B2 (ja) | 2025-10-22 |
| AU2022233704A9 (en) | 2023-08-24 |
| JP2024509244A (ja) | 2024-02-29 |
| AU2022233704A1 (en) | 2023-08-17 |
| CA3210369A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3886858T3 (pl) | Związki do leczenia chorób oka związanych z nadmiernym unaczynieniem | |
| IL287802A (en) | Preparations and methods for the treatment of eye diseases | |
| EP4100406A4 (en) | Compositions for treatment of ocular diseases | |
| EP4267196A4 (en) | TREATMENT OF NEUROLOGICAL DISEASES | |
| GB202001353D0 (en) | Treatment of skin conditions | |
| GB202015959D0 (en) | Treatment of diseases involving NAD | |
| EP4138841C0 (en) | FORMULATION FOR THE TREATMENT OF OPHTHALMIC CONDITIONS | |
| IL312447A (en) | Methods of treating sickle cell disease with Oxbryta | |
| EP4304631C0 (en) | TREATMENT OF EYE DISEASES WITH FRUCTOSYL-AMINOACID OXIDASE | |
| IL286578A (en) | Methods of diagnosis and treatment of liver diseases using obeticholic acid | |
| EP4313250A4 (en) | PERILSIONAL TREATMENT OF SKIN DISEASES | |
| GB202108485D0 (en) | Treatment of inflammatory conditions or diseases | |
| GB201914516D0 (en) | Treatment of eye disease | |
| GB202016710D0 (en) | Treatment of eye conditions | |
| HK40102829A (en) | Treatment of cns diseases with sgc stimulators | |
| CA3289675A1 (en) | Treatment of thyroid eye disease with satralizumab | |
| GB202004938D0 (en) | Treatment of Ophthalmological Conditions | |
| AU2024208107A1 (en) | Methods of treatment using bempedoic acid | |
| HK40084366A (en) | Treatment of panx1 associates diseases | |
| GB202002291D0 (en) | Treatment of corneal vasularisation | |
| HK40089625A (en) | Treatment of respiratory diseases with amino acid compounds | |
| AU2024902833A0 (en) | Treatment of diseases associated with mitophagy | |
| HK40105294A (zh) | 近视治疗 | |
| IL321175A (en) | Treatment methods with tardifitant | |
| HK40103935A (en) | Compositions for treatment of conditions and diseases associated with polycystin expression |